Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 04:00:02 2026-01-12 pm EST			Pre-market 07:26:55 pm
109.19 ^USD	-1.21%		109.50	+0.28%

Jan. 12	Moderna expects $1.9 billion in sales, trims costs forecast for 2025	RE
Jan. 09	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Transcript : Merck & Co., Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01

Published on 12/03/2025 at 04:06 pm EST - Modified on 12/05/2025 at 05:25 pm EST

S&P Capital IQ

Presenter Speech
Geoffrey Meacham (Analysts)

Second day of the Citi Global Healthcare Conference. So my name is Geoff Meacham, I'm the senior biopharma analyst. I have Mary Kate Davis with me as well

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Merck & Co., Inc.

Jan. 12	Moderna expects $1.9 billion in sales, trims costs forecast for 2025	RE
Jan. 09	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Jan. 09	Sector Update: Health Care Stocks Mixed Friday Afternoon	MT
Jan. 09	Sector Update: Health Care	MT
Jan. 09	Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals	MT
Jan. 09	Morgan Stanley Adjusts Price Target on Merck to $101 From $102, Maintains Equalweight Rating	MT
Jan. 09	Wall Street Gains Momentum Amid Jobs Report as US Equity Futures Edge Higher Pre-Bell	MT
Jan. 09	Morgan Stanley Trims Price Target on Merck to $101 From $102, Keeps Equalweight Rating	MT
Jan. 09	Merck reportedly consiering a major acquisition (Revolution Medicines)
Jan. 09	Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal	CI
Jan. 08	AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty	RE
Jan. 08	Merck & Co. in Talks to Acquire Revolution Medicines	MT
Jan. 08	Price tag of $28bn to $32bn was being discussed as part of Merck-Revolution Medicines deal - FT	RE
Jan. 08	Merck in talks to buy biotech Revolution in up to $32 billion deal, FT reports	RE
Jan. 08	Merck in talks to buy biotech Revolution Medicines, Financial Times reports	RE
Jan. 08	Merck in talks to buy cancer drugmaker Revolution Medicines-FT	RE
Jan. 08	Merck Shares Rise After Wolfe Research Upgrade	MT
Jan. 08	Rothschild & Co Redburn Adjusts Merck Price Target to $135 From $125, Maintains Buy Rating	MT
Jan. 08	Independent expert group to review HPV vaccine evidence after US recommendation change	RE
Jan. 08	Wolfe Research Upgrades Merck & Co. to Outperform From Peer Perform, Price Target is $135	MT
Jan. 07	UBS Adjusts Price Target on Merck & Co to $130 From $105, Maintains Buy Rating	MT
Jan. 07	Vaxxas appoints former Merck global vaccines president David Peacock as CEO	RE
Jan. 07	Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC	CI
Jan. 07	Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer	MT
Jan. 07	Merck Successfully Completes Cash Tender Offer for Cidara Therapeutics	MT